 HYDERABAD, India PRINCETON, N.J.--BUSINESS WIRE--Dr. Reddys Laboratories Ltd. BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as Dr. Reddys today announced the launch of Vigabatrin Tablets USP, 500 mg, a therapeutic equivalent generic version of Sabril vigabatrin Tablets, USP, approved by the U.S. Food and Drug Administration USFDA. We are pleased that this product has been designated as a Competitive Generic Therapy CGT 